Form 4: Arcturus Therapeutics Director Moncef Slaoui Acquires Stock Options

Director Moncef Slaoui acquired stock options in Arcturus Therapeutics Holdings Inc. on June 19, 2024.

Summary

• Moncef Slaoui, a director of Arcturus Therapeutics Holdings Inc., acquired stock options on June 19, 2024.
• The options are for 15,000 shares and 14,794 shares of common stock, with an exercise price of $25.96.
• The options vest monthly over two years and one year respectively, and expire on June 19, 2034.
• Following the transaction, Slaoui directly owns options for 15,000 and 14,794 shares.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment, but rather reports a transaction.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if interpreted as a sign of confidence by the director.

Key Dates